Cardiovascular Systems (CSI), a provider of orthopedic solutions, is set to exhibit 12-month data from its Compliance 360° study.

The prospective, randomized trial, which enrolled 50 patients, was designed to compare the treatment of above-the-knee calcified lesions using the company’s Diamondback orbital atherectomy system, followed by low-pressure balloon angioplasty, to balloon angioplasty alone.

The study examines whether Diamondback orbital atherectomy system can achieve satisfactory acute and long-term results without the need for stent placement.

The Diamondback system is used as a minimally invasive therapy to treat patients with peripheral arterial disease (PAD), blockages in leg arteries.

The company said it will present data at the american college of cardiology’s (ACC’s) 61st annual scientific session & expo McCormick place south in Chicago from 24-27 March 2012.